Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pneumococcal Conjugate Vaccine 13 (PCV13) Schedule Change From 3+0 to 2+1 to Accelerate Reduction in Pneumococcal Vaccine Serotype Carriage in Blantyre, Malawi: an Effectiveness Study

NCT04078997 is registered in ClinicalTrials.gov with University of Liverpool as lead sponsor.

NCT NCT04078997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04078997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pneumococcal Conjugate Vaccine 13 (PCV13) Schedule Change From 3+0 to 2+1 to Accelerate Reduction in Pneumococcal Vaccine Serotype Carriage in Blantyre, Malawi: an Effectiveness Study
Lead sponsor
University of Liverpool
Phase
Observational
Overall status
Completed
Start date
July 21, 2019
Completion date
February 16, 2024
Enrollment
3,507 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

13-valent pneumococcal vaccine, streptococcus pneumoniae